[Will cyclosporin A be used in the treatment of refractory nephrotic syndromes?].
In the treatment of nephrotic syndromes complicating primary glomerulonephritis anti-inflammatory and immunosuppressive action of glucocorticoids is used most frequently. Cases refractory to corticotherapy are a difficult clinical problem and lead, most frequently, to renal failure. Recently trials have been carried out of replacing glucocorticoids with the immunosuppressant which is devoid of the dangerous side effects of cytostatics, i.e. cyclosporin A. Theoretical and experimental data relevant to the use of cyclosporin A in the treatment of glomerulopathies are presented and the results of clinical studies carried out as yet, and therapeutic prospects are discussed.
Hruby
Z
Z
D003524:Cyclosporins / Q000627:therapeutic use*; D004351:Drug Resistance; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents; D009402:Nephrosis, Lipoid / Q000188:drug therapy* / Q000276:immunology; D009404:Nephrotic Syndrome / Q000188:drug therapy* / Q000276:immunology
D003524:Cyclosporins; D005938:Glucocorticoids; D007166:Immunosuppressive Agents
Czy cyklosporyna A znajdzie zastosowanie w leczeniu opornych zespołów nerczycowych?